Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Pieter van Paassen, Matthijs C. Brouwer et al.|The Lancet Respiratory Medicine|2022

Cited by 143